Organic Acids
Medchemexpress LLC Pam2CSK4 (TFA) | 99.5% | 1271.82 (free base) | 5 MG
Pam2CSK4 (TFA) is a lipopeptide that acts as a TLR6-independent TLR2 ligand and agonist. It promotes platelet aggregation and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages.
- Acts as a TLR6-independent TLR2 ligand and agonist.
- Promotes platelet aggregation.
- Increases platelet adhesion to collagen-coated surfaces.
- Activates iNOS expression and NO production in mouse macrophages.
Medchemexpress LLC Apstatin trifluoroacetate | 99.4% | 573.56 g/mol | C25H34F3N5O7 | 5 MG
Apstatin TFA is the trifluoroacetate salt of apstatin, a potent aminopeptidase P (APP) inhibitor with reported Ki values of 2.6 μM (rat) and 0.64 μM (human). It has been used in preclinical studies showing cardioprotective effects and is supplied as a solid research compound for biochemical and pharmacological applications.
- Potent aminopeptidase P inhibitor with reported Ki values of 2.6 μM (rat) and 0.64 μM (human).
- Demonstrated cardioprotective effects in preclinical studies.
- Supplied as a solid with reported purity of 99.43%.
- Molecular formula C25H34F3N5O7 and molecular weight 573.56 g/mol.
- Recommended storage: powder -80°C (2 years) or -20°C (1 year); protect from moisture.
- Available in small research pack sizes suitable for preclinical experiments.
Medchemexpress LLC 6bK TFA | 1774353-12-6 | 99.7% | 871.94 | 10 MG
6bK TFA is a potent and selective inhibitor of insulin degrading enzyme (IDE) with an IC50 value of 50 nM. It increases circulating insulin in high-fat-fed mice and enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice. This product is suitable for type 2 diabetes research.
- Potent and selective inhibitor of insulin degrading enzyme (IDE)
- Increases circulating insulin in high-fat-fed mice
- Enhances glucose tolerance to oral glucose
- Suitable for type 2 diabetes research
- For research use only
Medchemexpress LLC Relamorelin (TFA) | 2863659-22-5 | 99.8% | 905.00 | 50 MG
Relamorelin (TFA) | 2863659-22-5 | 99.8% | 905.00 | 50 MG
Medchemexpress LLC F11R peptide TFA | 97.6% | 1459.58 | 5 MG
F11R peptide TFA is an F11 receptor molecule that inhibits anti-F11R antibody-induced platelet aggregation and the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells. It can be used for research of atherosclerotic plaques and associated thrombotic disease.
- Inhibits anti-F11R antibody-induced platelet aggregation.
- Inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells.
Medchemexpress LLC DX600 TFA | 99.2% | 3074.33 (free acid) | 1 MG
DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM) that does not cross-react with ACE. It has been observed to exacerbate diabetes-induced cardiovascular dysfunction and increase cardiac and renal NOX activity. It is for research use only.
- Selective ACE2 specific inhibitor
- Does not cross-react with ACE
- Exacerbates diabetes-induced cardiovascular dysfunction
- Increases cardiac and renal NOX activity
Medchemexpress LLC ATX-II TFA | 99.7% | 4934.62 (free acid) | 1 MG
ATX-II TFA is a selective sodium channel modulator toxin. It enhances late sodium current and prevents full sodium channel inactivation, leading to persistent current fractions. This can have pro-arrhythmic effects, such as slowing intrinsic heart rate and prolonging the QT interval. It is suitable for research on atrial fibrillation and long QT syndromes.
- Selective sodium channel modulator toxin
- Enhances late sodium current
- Prevents full sodium channel inactivation
- Generates persistent current fractions
- Has a pro-arrhythmic effect
- Slows intrinsic heart rate
- Prolongs QT interval
- Suitable for research on atrial fibrillation
- Suitable for research on long QT syndrome
- Purity of 99.7%
- Molecular weight of 4934.62 (free acid)
- Appearance as a solid
- White to off-white color
Medchemexpress LLC DPC-AJ1951 (TFA) | 99.4% | 1666.99 (free base) | 1 MG
DPC-AJ1951 TFA is a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). Its activity has been characterized in ex vivo and in vivo assays of bone resorption. In vitro, it induces intracellular Ca2+ mobilization in HEK 293 cells transfected with the human PPR.
- Acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR)
- Activity characterized in ex vivo and in vivo assays of bone resorption
- Induces intracellular Ca2+ mobilization in HEK 293 cells transfected with the human PPR
- 14 amino acid peptide
Medchemexpress LLC C-telopeptide TFA | 868.89 (free base) | 25 MG
C-telopeptide TFA is a cross-linked peptide of type I collagen. It is released during bone resorption and has been correlated with bone mineral density (BMD). This product is intended for research use only.
- Cross-linked peptide of type I collagen
- Released during bone resorption
- Correlated with bone mineral density (BMD)
- Sequence: Glu-Lys-Ala-His-Asp-Gly-Gly-Arg
- Target: MMP
- Pathway: Metabolic Enzyme/Protease
Medchemexpress LLC Liraglutide TFA | 99.6% | 3751.20 | 5 MG
Liraglutide (TFA) is an agonist of the glucagon-like peptide 1 receptor (GLP-1). It can activate GLP-1, resulting in the release of insulin when glucose concentration is elevated. Additionally, Liraglutide (TFA) reduces glucagon secretion in a glucose-dependent manner and can be utilized in research concerning type 2 diabetes.
- Agonist of glucagon-like peptide 1 receptor (GLP-1)
- Activates GLP-1, which leads to insulin release in the presence of increased glucose concentration
- Reduces glucagon secretion in a glucose-dependent manner
- Can be studied in research on type 2 diabetes
Medchemexpress LLC Lys-bradykinin TFA | 99.9% | 1188.38 g/mol | C56H85N17O12 · x C2HF3O2 | 50 MG
Lys-Bradykinin TFA is the trifluoroacetate salt of Lys-Bradykinin (kallidin), a biologically active nonapeptide ligand for bradykinin/kallidin receptors. Supplied as a solid peptide powder for research use, it is commonly used in studies of vascular regulation, inflammation, and receptor pharmacology.
- Trifluoroacetate salt of Lys-Bradykinin (kallidin).
- Purity 99.85%.
- Molecular weight 1188.38 g/mol.
- Available as solid powder, including 50 MG size.
- Storage: powder -80°C for 2 years, -20°C for 1 year; in solvent -80°C for 6 months, -20°C for 1 month.
- Documentation includes COA, RP-HPLC, LCMS, elemental analysis, and SDS.
Medchemexpress LLC EZM0414 (TFA) | 2411759-92-5 | 95.48% | 514.51 | 50 MG
EZM0414 TFA is the trifluoroacetic acid salt form of EZM0414. It is a potent, selective, and orally active inhibitor of SETD2, researched for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma.
- Potent and selective SETD2 inhibitor
- Orally active
- Inhibits proliferation of MM and DLBCL cell lines
- Shows robust tumor growth regressions in xenograft models
- High oral bioavailability in rats and mice
Medchemexpress LLC GsMTx4 TFA | 99.9% | 4095.84 | 1 MG
GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. It also blocks cation-selective stretch-activated channels (SACs) and attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity, making it a pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology.
- Selectively inhibits cationic-permeable mechanosensitive channels (MSCs)
- Blocks cation-selective stretch-activated channels (SACs)
- Attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity
- Attenuates microglial reactivity
- Useful as a pharmacological tool for identifying the role of excitatory mechanosensitive channels
Medchemexpress LLC Pyridostatin (TFA) | 1472611-44-1 | 1037658 | C33H33F3N8O7 | 25 MG
Pyridostatin TFA is a G-quadruplex DNA stabilizing agent with a Kd of 490 nM, targeting both DNA and RNA G4s within cells. This selective small molecule promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage and affects proto-oncogene Src.
- Targets DNA and RNA G4s in cells
- Promotes growth arrest in human cancer cells
- Induces replication- and transcription-dependent DNA damage
- Reduces SRC protein levels and cellular motility in breast cancer cells
- Causes neurite retraction, synaptic loss, and dose-dependent neuronal death in cultured primary neurons
- Induces DNA DSBs in cultured primary neurons
- Downregulates BRCA1 protein at the transcriptional level
- High purity: 99.17%
- Solid, white to off-white appearance
Medchemexpress LLC Cyclo(RGDyC) TFA | 95.68% | 594.64 | 1 MG
Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. It can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer.
- Cyclic pentapeptide
- Anti-angiogenic abilities
- Contains the alphaVbeta3 integrin-binding sequence arginine-glycine-aspartate (RGD)
- Can be used to target tumors and ocular neovasculature
- White to off-white solid appearance
- Soluble in H2O